Amgen Inc to boost dividend 31% for first quarter of 2013

By Admin
Amgen Inc said it will raise its dividend 31% for the first quarter of next year and buy back the additional $2 billion in shares. The worlds largest b...

Amgen Inc said it will raise its dividend 31% for the first quarter of next year and buy back the additional $2 billion in shares. The world’s largest biotechnology company will pay stockholders 47 cents on March 7, the Thousand Oaks, said.

Amgen became the first biotechnology company to pay a dividend in July 2011. The current payment is 36 cents and the analyst estimated a rise to 40 cents.

The biotechnology firm is looking for new products and buyouts to up revenue as its earlier core anemia business fell. On Dec 10, the company had agreed to acquire DeCode Genetcs Inc, a genetics research company, for $415 million.

Besides, earlier this year, Amgen bought Micromet Inc for $1.16 billion to add an experimental leukemia drug. It also signed a development deal with London-based AstraZeneca Plc and also boosted its presence in the cancer market through sales of Xgeva, a bone drug that reduces fractures.

The company also said it has authorized further share repurchase with $500 million left to spend from its present $10 billion program.

Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. It was the first company to realize the new science’s promise by bringing safe, effective medicines from lab, to manufacturing plant to patient. 

Share
Share

Featured Articles

Hyfe AI uses acoustic AI in its digital cough monitoring

Hyfe uses acoustic AI in its digital cough monitoring. Dr. Joe Brew, Co-Founder & CEO of Hyfe AI, tells us more about coughing technology post-COVID-19

Siemens: smart finance to help medical technology growth

Penny Pinnock, Business Development Manager at Siemens Financial Services UK, discusses how adopting digital technology can support the healthcare sector

Healthcare Digital news roundup: prostate cancer & AI

This week in Healthcare Digital, we heard from experts in the sector: Trevor Dearing from Illumio, Avenda Health’s Brit Berry-Pusey & Vish Charan of Abbott

Lexica shares post-COVID-19 digital healthcare trends

Digital Healthcare

Medical devices expanding senior healthcare innovation

Medical Devices & Pharma

Abbott’s CRM medical devices can help cardiac arrhythmia

Medical Devices & Pharma